By expenditures
| Name | Title | Type |
|---|---|---|
| Ron Marklund | Principal | Auditee |
| Ashley Barsema | Signing Director | Auditee |
| Marcela Rodriguez | Co-Executive Director | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 392652 | 2025 | 2026-03-18 | DUGAN + LOPATKA CPAS | $1.05M |
| 348960 | 2024 | 2025-03-27 | Dugan + Lopatka CPAS | $1.97M |
| 301111 | 2023 | 2024-03-29 | Cliftonlarsonallen LLP | $2.42M |
| 3817 | 2022 | 2023-11-20 | Cliftonlarsonallen LLP | $1.67M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 301111 | 2023 | 2024-03-29 | 966666 | 2023-005 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 966665 | 2023-005 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 966664 | 2023-005 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 966663 | 2023-004 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 966662 | 2023-004 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 966661 | 2023-004 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 966660 | 2023-003 | Significant Deficiency | Yes | L |
| 301111 | 2023 | 2024-03-29 | 966659 | 2023-003 | Significant Deficiency | Yes | L |
| 301111 | 2023 | 2024-03-29 | 966658 | 2023-003 | Significant Deficiency | Yes | L |
| 301111 | 2023 | 2024-03-29 | 390224 | 2023-005 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 390223 | 2023-005 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 390222 | 2023-005 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 390221 | 2023-004 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 390220 | 2023-004 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 390219 | 2023-004 | Material Weakness | - | I |
| 301111 | 2023 | 2024-03-29 | 390218 | 2023-003 | Significant Deficiency | Yes | L |
| 301111 | 2023 | 2024-03-29 | 390217 | 2023-003 | Significant Deficiency | Yes | L |
| 301111 | 2023 | 2024-03-29 | 390216 | 2023-003 | Significant Deficiency | Yes | L |
| 3817 | 2022 | 2023-11-20 | 578681 | 2022-008 | Significant Deficiency | - | B |
| 3817 | 2022 | 2023-11-20 | 578680 | 2022-006 | Material Weakness | Yes | B |
| 3817 | 2022 | 2023-11-20 | 578679 | 2022-008 | Significant Deficiency | - | B |
| 3817 | 2022 | 2023-11-20 | 578678 | 2022-008 | Significant Deficiency | - | B |
| 3817 | 2022 | 2023-11-20 | 578677 | 2022-007 | Significant Deficiency | Yes | L |
| 3817 | 2022 | 2023-11-20 | 578676 | 2022-006 | Material Weakness | Yes | B |
| 3817 | 2022 | 2023-11-20 | 578675 | 2022-006 | Material Weakness | Yes | B |
| 3817 | 2022 | 2023-11-20 | 578674 | 2022-006 | Material Weakness | Yes | B |
| 3817 | 2022 | 2023-11-20 | 2239 | 2022-008 | Significant Deficiency | - | B |
| 3817 | 2022 | 2023-11-20 | 2238 | 2022-006 | Material Weakness | Yes | B |
| 3817 | 2022 | 2023-11-20 | 2237 | 2022-008 | Significant Deficiency | - | B |
| 3817 | 2022 | 2023-11-20 | 2236 | 2022-008 | Significant Deficiency | - | B |
| 3817 | 2022 | 2023-11-20 | 2235 | 2022-007 | Significant Deficiency | Yes | L |
| 3817 | 2022 | 2023-11-20 | 2234 | 2022-006 | Material Weakness | Yes | B |
| 3817 | 2022 | 2023-11-20 | 2233 | 2022-006 | Material Weakness | Yes | B |
| 3817 | 2022 | 2023-11-20 | 2232 | 2022-006 | Material Weakness | Yes | B |